Prediction of Antimicrobial Resistance and Genomic Profiling of Bacterial Isolates in Adult Cancer Patients With Blood Stream Infection.
Sponsor study identifier
observational
200
1 country
1
Study Start
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Sepsis and bloodstream infection (BSI) are among the most serious complications in patients with cancer, in whom disease- and treatment-related immunosuppression markedly increases susceptibility to infection. Sepsis accounts for approximately 15% of ICU admissions in this population, and short-term mortality is consistently higher than in patients without cancer In haematological malignancy, sepsis affects roughly 12-27% of patients within a year of diagnosis, and although in-hospital mortality has fallen over two decades, it remained higher than in non-cancer patients (23.1% vs 14.4% in 2021) .
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 13, 2026
Actual (reported)October 21, 2026
Actual (reported)November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Identification of bacterial isolates causing blood stream infection and determination of their antibiotic sensitivity
Blood Culture: BD BACTEC blood culture system. Identification and antibiotic sensitivity of bacterial isolates: VITEK® 2 Compact system (bioMérieux, France).
From enrollment up to 6 months.
Molecular characterization of bacterial isolates
A subset of bacterial isolates collected during the prospective phase will undergo molecular characterization to enable integration of molecular resistance determinants with clinical and laboratory variables.
From the end of enrollment up to 6 months.
Adult cancer patients with blood stream infections
Blood Culture: Blood samples will be collected under complete aseptic conditions. Blood culture bottles will immediately be transported to the Medical Microbiology Laboratory and tested using the BD BACTEC blood culture system. Identification and antibiotic sensitivity of bacterial isolates: Positive blood culture bottles will be identified and tested for antimicrobial sensitivity using the VITEK® 2 Compact system (bioMérieux, France).
Adult Cancer Patients with Blood Stream Infection
Sohag University Hospitals
Sohag, Egypt
Bianchi A, Mokart D, Leone M. Cancer and sepsis: future challenges for long-term outcome. Curr Opin Crit Care. 2024 Oct 1;30(5):495-501. doi: 10.1097/MCC.0000000000001173. Epub 2024 May 31.
Bachlitzanaki M, Aletras G, Ioannou P, Bachlitzanaki E, Hamilos G, Samonis G, Kofteridis D. Bloodstream Infections in Solid Malignancies: Risk Factors, Resistance Patterns, and Clinical Outcomes from a Two-Center Cohort in Heraklion, Crete. Life (Basel). 2026 Apr 24;16(5):720. doi: 10.3390/life16050720.
Blood samples
Mai Gamal Abdelnasser Abass Khalifa Dr Mai Khalifa, Assistant lecturer of Medical
CONTACT
First Submitted
October 13, 2026
First Posted
October 21, 2026
Study Start
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test
A subset of bacterial isolates collected during the prospective phase will undergo molecular characterization to enable integration of molecular resistance determinants with clinical and laboratory variables.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
October 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 23, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: